Galectin Therapeutics Inc expected to post a loss of 19  cents a share - Earnings Preview

Galectin Therapeutics

25/03/2022 12:48

* Galectin Therapeutics Inc  GALT.OQ   GALT.O  is expected
to show
no change in quarterly revenue when it reports  results on March
29 (estimated). 
    * ​Refinitiv's mean analyst estimate for Galectin
Therapeutics Inc
is for a loss of 19 cents per share. For the same quarter last
year, the company reported a loss of 13 cents per share.
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $14​, above​ its last closing price
of $1.77. ​​​

This summary was machine generated March 25 at 12:48 GMT.  All
figures in US dollars  unless otherwise stated